Literature DB >> 18173979

Update on gout: pathophysiology and potential treatments.

Aryeh M Abeles1, Jean Y Park, Michael H Pillinger, Bruce N Cronstein.   

Abstract

After several decades of senescence, the twin fields of hyperuricemia and gout have again regained attention in both the scientific and clinical spheres, and this review highlights several recent advancements. Specifically, we review newly discovered mechanisms of uric acid-induced inflammation, uric acid's putative role as a "danger signal" in innate immunity, the possible link between hyperuricemia and cardiovascular disease, and evolutionary evidence suggesting that hyperuricemia conferred a survival advantage in primates (when the gene for uricase was lost) several million years ago. Finally, we provide an overview of the current approach to gout, as well as what treatments are on the horizon.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18173979     DOI: 10.1007/s11916-007-0231-3

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  58 in total

Review 1.  Innate immune recognition.

Authors:  Charles A Janeway; Ruslan Medzhitov
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

Review 2.  Treatment of gout and crystal arthropathies and uses and mechanisms of action of nonsteroidal anti-inflammatory drugs.

Authors:  S B Abramson
Journal:  Curr Opin Rheumatol       Date:  1992-06       Impact factor: 5.006

3.  Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol.

Authors:  Pascal Richette; Thomas Bardin
Journal:  Nat Clin Pract Rheumatol       Date:  2006-06

4.  Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation.

Authors:  Ru Liu-Bryan; Peter Scott; Anya Sydlaske; David M Rose; Robert Terkeltaub
Journal:  Arthritis Rheum       Date:  2005-09

5.  MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals.

Authors:  Chun-Jen Chen; Yan Shi; Arron Hearn; Kate Fitzgerald; Douglas Golenbock; George Reed; Shizuo Akira; Kenneth L Rock
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

6.  Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils.

Authors:  B N Cronstein; Y Molad; J Reibman; E Balakhane; R I Levin; G Weissmann
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

7.  Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study.

Authors:  Leo K Niskanen; David E Laaksonen; Kristiina Nyyssönen; Georg Alfthan; Hanna-Maaria Lakka; Timo A Lakka; Jukka T Salonen
Journal:  Arch Intern Med       Date:  2004-07-26

8.  Purine-rich foods, dairy and protein intake, and the risk of gout in men.

Authors:  Hyon K Choi; Karen Atkinson; Elizabeth W Karlson; Walter Willett; Gary Curhan
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

Review 9.  Uric acid: role in cardiovascular disease and effects of losartan.

Authors:  Michael Alderman; Kala J V Aiyer
Journal:  Curr Med Res Opin       Date:  2004-03       Impact factor: 2.580

Review 10.  A concise history of gout and hyperuricemia and their treatment.

Authors:  George Nuki; Peter A Simkin
Journal:  Arthritis Res Ther       Date:  2006-04-12       Impact factor: 5.156

View more
  2 in total

Review 1.  Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations.

Authors:  Allison Guttmann; Svetlana Krasnokutsky; Michael H Pillinger; Adey Berhanu
Journal:  Ther Adv Drug Saf       Date:  2017-09-13

Review 2.  Relationship between hyperuricemia with deposition and sexual dysfunction in males and females.

Authors:  A Sansone; Y Reisman; E A Jannini
Journal:  J Endocrinol Invest       Date:  2022-01-08       Impact factor: 5.467

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.